STAGE IVA PROSTATE CANCER AJCC V8
Clinical trials for STAGE IVA PROSTATE CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IVA PROSTATE CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IVA PROSTATE CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo tested for Tough-to-Treat prostate cancer
Disease control TerminatedThis study tested a combination of two drugs, apalutamide and abiraterone, along with prednisone, in men whose prostate cancer had spread and stopped responding to standard hormone therapy. The goal was to see if this combination could slow cancer growth. Only 7 men took part bef…
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 16, 2026 22:35 UTC
-
Experimental drug targets Hard-to-Treat prostate cancer
Disease control TerminatedThis study tested the drug erdafitinib in 11 men with advanced prostate cancer that had spread to the bones and stopped responding to hormone therapy. The goal was to see if erdafitinib could help control the cancer by blocking certain growth signals. Researchers also collected b…
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
Experimental combo aims to outsmart drug-resistant prostate cancer
Disease control TerminatedThis early-phase trial tested a new combination of two drugs—decitabine/cedazuridine and enzalutamide—in 8 men with advanced prostate cancer that had stopped responding to standard treatment. The goal was to find a safe dose and see if the combination could reverse drug resistanc…
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
New PET scan agent aims to map hidden prostate cancer spread
Diagnosis TerminatedThis study tested a new imaging agent called 68Ga-PSMA-11 to see if it could give clearer pictures of where prostate cancer has spread in men with advanced, treatment-resistant disease. The goal was to help doctors better understand the location of tumors. The study was terminate…
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: Thomas Hope • Aim: Diagnosis
Last updated Jun 16, 2026 12:49 UTC
-
Radioactive treatment for bone pain in advanced prostate cancer tested, but study stopped early
Symptom relief TerminatedThis study tested a radioactive drug called Sn-117m-DTPA to see if it could reduce bone pain in men with prostate cancer that had spread to their bones and no longer responded to hormone therapy. Only one person enrolled before the study was stopped. The goal was to measure pain …
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Symptom relief
Last updated May 27, 2026 12:02 UTC